Marcelle Machluf is full professor and dean of the Faculty of Biotechnology and Food Engineering at the Technion Haifa Israel. Marcelle Machluf holed a PhD degree from the Faculty of Chemical Engineering the unit of Biotechnology, Ben Gurion University Bear Sheva, in Liposomes and polymer delivery for vaccines development. Prof Machluf had a post-doctoral fellowship of five years experience in drug delivery, gene therapy and tissue engineering in Harvard Medical School, Boston MA, US. Professor Machluf laboratory focuses in the drug delivery area, based on a novel delivery system that is based on cell membrane of stem cells and is termed Nanoghosts. Another area of research is tissue engineering, developing scaffolds for that are focused on natural isolated extracellular matrix (ECM), and which are modulated to allow injectable, microcapsule or other 3D platforms formation. Prof Machluf has an Adjunct Professor position in the prestigious School of Material Science Engineering (NTU, Singapore) Singapore. Her group, which consists of 15 PhD students, 3 postdoc and 2-research assistances. Professor Machluf has published more than 90 papers (among which Nature Biotec, Nano Letters, Cancer Research, J of Controlled Release) and chapters in books. She has 8 patents in national phase and 4 international approved ones in the field of drug delivery and tissue engineering. Prof Machluf is on the editorial board of several journals among which are Scientific Report and Tissue Engineering and part of the Minerva Programe Committee, under the Max-Planck Institute (Germany). She is currently the President of the Israeli controlled release society. Her work in drug delivery was selected by the Israel Ministry of Science and Technology as one of Israel’s sixty most impactful scientists for developments in the field of advanced cancer therapies. She was also chosen to light the torch for the 70th independent year of the state of Israel. Lady Globes Magazine selected her as the Women of the Year (2018). In November 2019 Prof Machluf has founded a startup company” NanoGhost” for the therapy of Cancer and raised 5M$ to support the scale-up process of the platform until reaching Phase 1 clinical studies.
Faculty:Biotechnology and Food Engineering